Pharmacokinetic Evaluation of Moxifloxacin IV to Enteral Switch Therapy in Intensive Care Patients

University Hospital, Ghent4 enrolled

Overview

In the Intensive Care (IC)-unit moxifloxacin treatment is often started with intravenous administrations. As moxifloxacin is known to have a high oral bioavailability in healthy volunteers, patients are switched to oral or enteral therapy as soon as possible. However, no data on plasma levels for moxifloxacin during such a switch-therapy in IC-patients are available. Therefore, this study aims to evaluate the moxifloxacin-plasma levels and their inter-individual variability during IV to enteral switch therapy in IC-patients.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Pneumonia

Interventions

IV and enteral administration of moxifloxacinDRUG

IV and enteral administration of moxifloxacin

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * IC patients treated with 400 mg moxifloxacin IV (once a day) that can be switched to enteral administration of 400 mg moxifloxacin. * IV steady state * Hemodynamic stability * Normal enteral feeding without prokinetics * Presence of arterial line * Informed consent * ≥ 18 jaar Exclusion Criteria: * Dialysis patients * Creatinine clearance \< 30 ml/min * Transaminase levels \> 5x upper limit

Locations (1)

University Hospital Ghent

Ghent, Belgium

Outcomes

Primary Outcomes

Pharmacokinetics

Pharmacokinetics will be followed.

Time frame: 2 days

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.